Anavex Life Sciences Reports Promising Results from Parkinson’s Disease Study

Anavex Life Sciences has announced encouraging preliminary results from their ANAVEX®2-73 (blarcamesine) Phase 2 extension study, targeting Parkinson’s disease dementia. This 48-week open-label study demonstrated notable improvements in patients’ symptoms, reinforcing the potential efficacy of ANAVEX®2-73. Parkinson’s disease is a chronic and progressive neurodegenerative disorder affecting millions worldwide. Current treatments focus primarily on symptom management, […]

Edgard Corona’s Approach to Democratizing Fitness in Latin America

 Edgard Corona, the visionary behind SmartFit, has fundamentally altered the fitness landscape in Latin America. Through his innovative business model, Corona has successfully democratized fitness, making it accessible to millions who might otherwise have been excluded from high-quality fitness experiences. His approach to achieving this  goal is a masterclass in entrepreneurship, combining strategic pricing, expansive […]

Anavex Life Sciences Reports Positive Results in Parkinson’s Disease Dementia Trial

 Anavex Life Sciences has announced promising findings from the extension phase of its phase 2 study assessing ANAVEX2-73 (blarcamesine) for Parkinson’s disease dementia (PDD). The open-label extension (OLE) study spanned 48 weeks and demonstrated significant improvements in clinical symptoms among participants who resumed treatment.  The trial faced an initial delay due to the COVID-19 pandemic, […]